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Abstract
Malignancy is one of the most common causes of hypercalcemia, particularly in cancer associated with bone metastases. Hypercalcemia occurs in up to 20% to 30% 
of cancer patients at some time during the course of their disease. Clinical manifestations of hypercalcemia vary in calcium level in blood. Signs and symptoms of 
hypercalcemia occur when the serum calcium level rises above those ranges. Fluids are first-line treatment with hypercalcemia followed by bisphosphanates if the 
calcium is high and the patient is experiencing symptoms. Various other medications are used as second-line agents in hypercalcemia of malignancy.
Introduction
Hypercalcemia is defined as a condition in which the serum 
calcium level is above normal level (> 10.5 mg/dL or ionized Ca 
level > 5.6 mg/dL). The consequences of abnormal serum calcium 
level can range from asymptomatic to life-threatening. In addition, 
excessively high serum calcium level causes clinical manifestations 
that affect the neuromuscular, gastrointestinal, renal, skeletal, and 
cardiovascular systems [1,2]. Malignancy is one of the most common 
causes of hypercalcemia, particularly in cancer associated with bone 
metastases. Since some tumor cells can resorb or destroy bone directly, 
hypercalcemia develops more rapidly and more aggressively than other 
causes of hypercalcemia, along with classic symptoms of dehydration, 
anorexia, nausea/vomiting, constipation, and polyuria. In multiple 
myeloma, for example, malignant myeloma cells secrete a cytokine 
(IL-6 receptor) that activate osteoclasts in vicinity of the myeloma cells 
leading to bone resorption. Hypercalcemia associated with malignancy 
is a common complication of some types of cancer, including 
squamous cell carcinomas, multiple myeloma, T-cell lymphoma, and 
breast carcinoma. 
Epidemiology and etiology
The most common causes of hypercalcemia in the United States are 
primary hyperthyroidism and malignancy. Hypercalcemia occurs in 
up to 20% to 30% of cancer patients at some time during the course of 
their disease, and predominantly encountered in hospitalization case, 
whereas primary hyperthyroidism accounts for the majority of cases in 
outpatient case [1,2] 
Pathophysiology
There are our major types of hypercalcemia associated with cancer: 
humoral hyperclacemia of malignancy, local osteolytic hypercalcemia, 
calcitriol-secreting lymphoma, and ectopic hyperparathyroidism [1]. 
Humoral hypercalcemia of malignancy (HHM) is the most common 
mechanism of hypercalcemia in the cancer patients. Many cancer 
cells secrete parathyroid hormone-related protein (PTHrP), which 
binds to the parathyroid receptors in bones and renal tissues, resulting 
in increased bone resorption and renal tubular reabsorption. This 
mechanism can be associated with any types of cancer, but it is most 
commonly associated with squamous-cell cancers (head/neck lung, 
esophagus, and skin), renal cancer, ovarian or endometrial cancer, 
breast cancer, and human T-cell leukemia virus-I associated with 
lymphoma [3]. The diagnosis of humoral hypercalcemia of malignancy 
can be confirmed by an elevated serum PTH-related protein. However, 
HHM is distinguished from primary parathyroidism by low level of 
parathyroid hormone and 1,25-dihydroxyvitamin D (calcitriol). Local 
osteolytic Hypercalcemia (LOH), account for about 20% of the cases 
of hypercalcemia of malignancy, is associated with extensive bone 
involvement by metastatic disease leading to high bone resorption and 
osteolytic lesions [3]. Tumor cells found in the bone marrow secrete 
stimulatory factors (IL-1 and 6, prostaglandin E2, TNF, PTHrP, 
and macrophage colony-stimulating factor) enhancing osteoclast 
activity [3]. Hypercalcemia patients associated with Local osteolytic 
Hypercalcemia are differentiated from Primary hyperthyroidism and 
Humoral hypercalcemia of malignancy by normal or slightly elevated 
PO4 levels, normal level of immunoreactive PTHrP, and presence 
of bone metastases or bone marrow infiltration [3]. This mechanism 
is typically associated with breast cancer, multiple myeloma, and 
lymphoma [1]. The other causes of hypercalcemia of malignancy are 
calcitriol-mediated hypercalcemia and ectopic PTH secretion. Those 
types are relatively rare causes of hypercalcemia, account for less than 
1% of cases. All histologic subtypes of lymphoma may produce the 
active form of vitamin D (calcitriol) that leads to increase absorption 
of calcium in intestine [3]. Ectopic hyperparathyroidism is the most 
rare cause of hypercalcemia in malignancy. It causes hypercalcemia as 
a result of the ectopic production and secretion of intact parathyroid 
hormone by neuroendocrine tumor [3].
Symptom overview
Clinical manifestations of hypercalcemia vary in calcium level in 
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blood. Normal range of serum calcium level is 8.5 to 10.5 mg/dL and 
normal range of ionized calcium level is 4 to 5.6 mg/dL. The severity of 
hypercalcemia is classified into three categories based on the level of 
total serum calcium (Figure 1).
Patients with mild to moderate hypercalcemia, which is total serum 
calcium between 10.5 and 12 mg/dL or of ionized calcium between 
5.6 to 8 mg/dL, can be asymptomatic [2]. The presenting signs and 
symptoms of hypercalcemia occur when the serum calcium level rises 
above those ranges. Patients with a chronic calcium level of 12 to 14 
mg/dL may tolerate those levels well, whereas sudden development of 
hypercalcemia in this range or higher may lead to dramatic changes 
in a patient’s mental status. The mnemonic “stones, bones, abdominal 
moans, and psychic groans” describes the constellation of symptoms 
and signs of hypercalcemia [2]. The clinical manifestations of 
hypercalcemia include: Central nervous system effects include lethargy, 
impaired concentration, fatigue, and muscle weakness; Renal effects 
include dehydration, polyuria, nocturia, nephrolithiasis resulting from 
hypercalciuria, nephrogenic diabetic insipidus, and nephrocalcinosis; 
Gastrointestinal effects include nausea, vomiting, anorexia, 
weight loss, constipation, abdominal pain, pancreatitis, and PUD; 
Cardiovascular effects include hypertension, shortened QT interval on 
electrocardiogram, cardiac arrhythmias, vascular calcification. Other 
symptoms include bone pain, arthritis, and osteoporosis. [2].
Treatment options (Dose, frequency, titration 
parameters, time to effect/symptom resolution, 
expected effects, special or target populations for 
specific therapies, side effects and their management)
The optimal therapy for hypercalcemia of malignancy is dependent 
on the severity of hypercalcemia and underlying causes. Hypercalcemia 
associated with malignancy would be resolved with definitive antitumor 
therapy of the underlying cancer with chemotherapy [3]. If it is not 
resolved with proper anticancer therapy, anti-hypercalcemic therapy 
focusing on targeting the pathophysiologic mechanisms should be 
considered. It is essential that withholding anti-hypercalcemic therapy 
may result in life-threatening emergency such as coma and death. 
Asymptomatic patients with mild hypercalcemia (serum Ca level 
of 10.5 to 12 mg/dL) generally do not require immediate treatment. 
The general supportive cares for hypercalcemia includes the removal 
calcium intake from any sources (IV, PO Ca supplements), an increase 
in oral free water intake, discontinuation of medications causing 
hypercalcemia (thiazide diuretics, lithium, vitamin D, carbonate 
therapy), an increase in the weight-bearing ambulation/activities, and 
discontinuation of sedative drugs analgesics [2]. Symptomatic patient 
with serum Ca levels greater than 12 mg/dL or patients with serum Ca 
levels greater than 14 mg/dL should be immediately and aggressively 
treated with anti-hypercalcemic therapy: hydration with saline 
rehydration followed by loop diuretics, calcitonin, bisphosphonates, 
and denosumab. For the majority of cancer patients with hypercalcemia 
have Humoral Hypercalcemia of malignancy (HHM) and Local 
Osteolytic Hypercalcemia (LOH), intravenous bisphosphonates or 
subcutaneous/intramuscular calcitonin or subcutaneous denosumab 
can be used to inhibit osteoclast-mediated bone resorption. Calcitriol-
mediated hypercalcemia is treated with intravenous glucocorticoid 
therapy along with limitation of calcium intake to inhibit vitamin D 
conversion to calcitriol. All pharmacologic therapy for hypercalcemia 
of malignancy is summarized in Table 1.
Hydration with normal saline followed by low-dose 
furosemide
Most patients with hypercalcemia associated with malignancy are 
dehydrated as a result of renal dysfunction induced by hypercalcemia 
and by decreased oral fluid intake resulting from nausea and vomiting. 
Therefore, the cornerstone of initial treatment of hypercalcemia is 
volume expansion with intravenous normal saline to increase the 
glomerular filtration rate and renal calcium excretion. Rehydration can 
be accomplished by IV normal saline at rate of 200 to 500 ml/hr or 
2 to 4 liter per day depending on renal function, the baseline status 
of dehydration, and the severity of hypercalcemia. Hydration with 
normal saline should be continued until patients are fully resuscitated, 
serum calcium level is corrected within the normal range, and the urine 
output is maintained at 200 ml/hr [1,2]. The hydration state is assessed 
by measuring fluid intake and output or by central venous pressure 
monitoring. However, the aggressive hydration can exacerbate heart 
failure in elderly patients, the use of hydration is limited in patients 
with congestive heart failure. Once intravascular volume has been 
restored, low-dose of furosemide (20-40mg IV) every 1 to 4 hours can 
be used to further lower the serum calcium level and or prevent the 
development of volume overload from normal saline administration; 
it block calcium reabsorption in the loop of Henle and increase urine 
output leading possible increased saline administration, which induces 
further calcium renal excretion [1].
Bisphosphonates; first-line medications
Bisphosphonate therapy should be initiated as soon as 
hypercalcemia is discovered, because it takes two to four days to appear 
the calcium level lowering effect. The maximum effect generally occurs 
within four to seven day after initiation of bisphosphonates. About 
60 to 90 percent of patients achieve their normal calcium level within 
four to seven days, and response last for one to three weeks [1]. Two 
bisphosphonate agents, Pamidronate (Aredia) and Zoledronic acid 
(Zometa), are approved by the U.S Food and Drug Administration 
for the treatment of hypercalcemia of malignancy. Bisphosphonates 
inhibit bone resorption and decrease bone mineralization by disrupting 
osteoclast activity. Most commonly reported adverse reactions are renal 
toxicity, flu-like symptoms, injection site reactions, hypocalcemia, 
hypophosphatemia, fatigue, muscle weakness, and constipation of 
diarrhea. Co-administration of oral calcium supplement of 500 mg and 
multiple vitamins containing 400 IU of vitamin D are recommended to 
 
Figure 1. Severity of hypercalcemia by serum total/ionized calcium level [2].
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Intervention MOA Dose Adverse Effects
Re-Hydration with NS Followed by Loop diuretics
IV Normal saline Enhance GFR and renal excretion of Ca2+ 200-500 ml/hr or 2-4 liter/day for 1 to 3 days depending on 
the cardiovascular and renal status of patient 
Volume overload; may exacerbate heart failure
Furosemide Inhibit Ca2+ resorption in the renal tube 20-40 mg IV; AFTER REHYDATION has been achieved Hypokalemia, renal failure, abnormalities of 
cardiac conduction
First-line medications: Intravenous Bisphosphonate
Pamidronate Inhibit osteoclast activity; decrease bone 
resorption
60-90 mg IV over 2 hr in a solution of 50-200 ml of NS or 
D5W Nephrotoxicity, flu-like symptoms with fever, 
chills, headacheZoledronic acid 4 mg IV over 15min in a solution of 50 ml NS or D5W
Second-line medications
Glucocorticoids Inhibit vitamin D conversion to calcitriol Oral prednisone 20-40 mg/day for 10 days, IV 
hydrocortisone 200 mg daily for 3 days or equivalents
Immune suppression, myopathy, ↑ glucose in 
blood, weight gain, ↑ blood pressure
Calcitonin [8] 4-8 IU/kg SQ or IM every 12 hour Inhibit bone resorption May rebound ↑ Ca2+ after 24 hours; cause 
vomiting, cramps, flushing
Mithramycin Inhibit osteoclast activity 25 mcg/kg over 4 to 6 hours in NS or D5w solution Bone marrow suppression, nephron/hepatic toxicity
Gallium nitrate [10] Inhibit osteoclast activity IV continuously infusion at 100-200 mg/m2 over 24 hours 
for five days
Bone marrow suppression, nephrotoxicity
Table 1. Pharmacologic options for Hypercalcemia associated with cancer.




- Available in 30 mg, 60 mg, or 
90 mg vials for IV administration; 
reconstituted with 10 ml of sterile water 
or D5W
- Moderate hypercalcemia: 60 to 90 mg 
as single dose IV infusion over 4 hours 
once every 3 to 4 weeks
- Severe hypercalcemia: 90 mg as single 
dose IV infusion over 24 hour
- Retreatment: Recommended that 
a minimum of 7 days elapse before 
retreatment to allow for full response to 
the initial dose.
- initial Ca lowering 
effect: 2-4 days
- maximum effects: 
about 4 to 7 days 
after initiation of 
therapy
- severe renal impairment (SCr 
> 3mg/ml or CrCr < 30ml/
minutes): reduced initial dose 
should be considered.
-Increase of SCr ≥ 0.5 mg/dL 
in patients with normal baseline 
(SCr < 1.4 mg/dL)
- Increase of SCr ≥ 1 mg/dL in 
patients with abnormal baseline 
(SCr ≥ 1.4 mg/dL)
SCr, electrolytes (Ca, PO4, 
Mg, K), CBC, hypocalcemia 
symptoms for at least 2 
weeks after therapy, dental 
exam prior to therapy, 
all cancer patients (pre-
existing anemia, leukopenia, 
thromobocytopenia) should 
be monitored during the first 
2 weeks of treatment; urine 
albumin every 3 to 6 months 
in multiple myeloma patients.
Contraindication: hypersensitivity 
to pamidronate or other 
bisphosphonates.
Pregnancy D:
there are no adequate and well-
controlled studies in pregnancy. 
However, adverse events were 
observed in animal reproduction 
studies. It is not known if 
pamidronate cross the placenta, but 





- Route: Intravenous 
- Available in 4 mg/5ml and 5mg/100ml 
vials for IV administration
- Hypercalcemia of malignancy 
(corrected Ca ≥ 12 mg/dL): 4 mg IV 
given as a single dose over 15 minutes. 
- Retreatment: wait at least 7 days 
before re-treatment; 4 mg as retreatment
- Similar to 
pamidronate. 
- Severe renal impairment (SCr 
> 4.5 mg/dL): evaluate risk Vs. 
benefit
- CrCL > 60 ml/min: 4 mg; no 
dosage adjustment is required.
- CrCL 50-60: reduced dose 
to 3.5 mg
- CrCL 40-49: reduced dose 
to 3.3 mg
- CrCL 30-39: reduced dose 
to 3 mg
- CrCL < 30: not recommended
Same as Pamidronate Contraindication: hypersensitivity 
to Zoledronic acid or other 
bisphosphonates.
Pregnancy D:
: there are no adequate and well-
controlled studies in pregnancy. 
Theoretically, there may be a risk 
of fetal harm when pregnancy 






- Available in 120 mg/1.7 mL (70 mg/
mL) solution in a single-use vial
- Treatment of hyperkalemia of 
malignancy: 120 mg subcutaneous 
every 4 week; give an additional 120 
mg on days 8 and 15 during the first 
month.
- About 85% patients 
within 3 days; 
maximal reductions 
observed within 1 
months
- Time to initial 
response: median 
time 9 days
- Time to complete 
response: median 
time 23 days
No hepatic/Renal dose 
adjustment
SCr, serum electrolytes 
(Ca, PO4, Mg), s/sx of 
hypocalcemia, infection, 
injection site reactions, dental 
exam
Limitation:
Denosumab is not indicated for 
the prevention of skeletal-related 
events in patients with multiple 
myeloma
Contraindication:
Hypersensitivity to Denosumab; 
Pre-existing Hypocalcemia
Pregnancy D:
Adverse events were observed in 
animal reproduction studies. 
Breast-feeding:
Not recommend
Table 2. First-line medication for hypercalcemia associated with cancer.
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prevent hypercalcemia [4-7].
Denosumab (Xgeva); Human monoclonal antibody; 
First-line medication
Denosumab, a full human IgG2 monoclonal antibody against 
RANKL, can be used for the management of hypercalcemia of 
malignancy in patients with persistent hypercalcemia despite 
bisphosphonates. Denosumab binds to RANKL (soluble protein 
essential for the formation, function, and survival of osteoclast), and 
inhibit osteoclast activity resulting in decreased skeletal-related events 
and tumor-induced bone destruction [8,9]. Unlike bisphosphonates, 
denosumab is not cleared by kidney, and there is no restriction of use 
in patients with chronic renal impairment whom bisphosphonates 
used with caution or contraindicated [4]. In a clinical trial, 33 patients 
with hypercalcemia of malignancy with persistently elevated serum 
calcium levels after treatment with zoledronic acid were treated with 
denosumab 120 mg subcutaneously weekly for 4 weeks and monthly 
thereafter [5]. In case reports of hypercalcemia patients with multiple 
myeloma and severe renal impairment, denosumab decreased serum 
calcium level within 2 to 4 days, and in one case was associated with 
improvement in renal function [9] (Table 2).
Second-line medications: Glucocorticoid, mithramycin, 
calcitonin, gallium nitrate
Glucocorticoids can be used in treatment option for hypercalcemia 
patients with excessive administration of vitamin D or the endogenous 
overproduction of calcitriol secondary to lymphoma [1]. In those 
condition, glucocorticoids such as oral prednisone 20-40 mg/day for 
10 days, IV hydrocortisone 200 mg daily for 3 days or equivalents [1,3].
Calcitonin can be used as alternative to saline hydration therapy 
for patients with severe chronic heart failure or moderate to severe 
renal dysfunction. The initiation of subcutaneous calcitonin may result 
in a more rapid reduction in serum calcium levels than other agents 
(maximal response occurs within 12 to 24 hours), but the effect and 
extent of serum calcium level reduction are often erratic [1]. 
Mitramycin (plicamycin), a potent cytotoxic antibiotic, reduce 
serum calcium level by inhibiting osteoclast-mediated bone resorption. 
Mithramycin is administered via IV infusion at 25 mcg/kg over 4 to 6 
hours in normal saline or D5w solution [1]. This therapy can be repeated 
daily for 3 to 4 days, and the serum calcium lowering effect begin to fall 
within 12 hours of initiation. However, mithramycin is not commonly 
recommended in hypercalcemia associated with malignancy due to 
dose-related adverse effects including nausea, vomiting, stomatitis, 
thrombocytopenia, and renal and hepatotoxicity.
Gallium nitrate is approved for treatment in hypercalcemia of 
malignancy. This agent decrease serum calcium level by inhibiting 
osteoclast activity. It is given via IV continuously infusion at 100-200 
mg/m2 over 24 hours for five days [1]. The common adverse events 
are renal dysfunction, hypocalcemia, hypophosphatemia, decreased 
serum bicarbonates, and hypotension. Since Administration of 
Gallium nitrate required continuous IV infusion over 24 hours, it is 
not commonly used [10-12]. 
Summery
Hypercalcemia of malignancy is a one of the most common 
complication of advanced breast cancer, squamous cell cancers, and 
multiple myeloma. Those types of cancer are highly associated with 
bone metastases or skeletal involvement. Therefore, hypercalcemia 
develops more quickly than other causes such as parathyroid hormone-
related, medications-related, vitamin D-related, and genetic disorders 
[2]. The development of this cancer-associated with complication is 
associated with a poor prognosis, and severe/acute hypercalcemia leads 
to severe mental impairment, renal failure, and life-threatening medical 
emergency. Clinical manifestations of hypercalcemia vary in the level 
of calcium in the blood, and the severity of hypercalcemia is classified 
into three categories based on the serum calcium level: mild, moderate, 
hypercalcemic crisis [2]. There are four mechanisms of hypercalcemia 
in the cancer patient: humoral hyperclacemia of malignancy, local 
osteolytic hypercalcemia, calcitriol-secreting lymphoma, and ectopic 
hyperparathyroidism [1,3]. Humoral hyperclacemia of malignancy 
and local osteolytic hypercalcemia are most common causes of 
hypercalcemia of malignancy, and the others are relatively rare causes 
of hypercalcemia, which account for less than 1% of cases. For the 
clinical intervention in the management of hypercalcemia, aggressive 
hydration with normal saline and intravenous bisphosphonates 
are first-line pharmacological options. Since most patients with 
hypercalcemia are dehydrated as a result of renal dysfunction induced 
by hypercalcemia or by decreased in oral fluid intake from nausea/
vomiting, hydration with normal saline should be initiated to increase 
the glomerular filtration rate and renal calcium excretion. In addition, 
volume expansion with normal saline dilutes calcium concentration in 
the blood, and inhibits calcium reabsorption in the proximal nephron; 
saline act as calciuretic [1]. After rehydration has been achieved, 
Loop diuretic, low-dose of furosemide can be used to prevent volume 
overload and to induce further renal calcium excretion. Intravenous 
bisphosphonates and subcutaneous denosumab can be used for 
severe hypercalcemia associated with cancer; those agents inhibit 
osteoclast activity and decrease bone resorption. Bisphosphonate 
agents, pamidronate and zoledronic acid, are not metabolized and 
are exclusively eliminated by renal excretion [6,7]. Therefore, dose 
of those agents are should be adjusted by patient’s renal function, 
and are contraindicated in patients with severe renal impairment. 
Denosumab is also first-line option for hypercalcemia associated with 
malignancy, but it is not commonly used as first-line due to high cost; 
its generic version is not available in the United States and price is 
much expensive than generic version of bisphosphonates. Therefore, 
denosumab can be used as alternative to bisphosphonates for patients 
with severe renal impairment. There are several agents could be 
used as second-line option when bisphosphonates are ineffective 
or contraindicated. Glucocorticoid is not commonly used, but it is 
effective in hypercalcemia-induced by endogenous overproduction 
of calcitriol or excessive ingestion of vitamin D. Calcitonin is safe and 
nontoxic, and its serum calcium lowering effect is much faster than 
other agents. However, the efficacy of calcitonin is often erratic, and the 
duration of calcium lowering effect is relatively short [2]. Mithramycin 
is not commonly used in hypercalcemia of malignancy due to its severe 
adverse effects. Finally, gallium nitrate is also approved for treatment, 
but the need of continuous IV infusion over 24 hours for 5 days limits 
its use in hypercalcemia of malignancy [1].   
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